Hitting a complex target: an update on interleukin-6 trans-signalling

Bibliography

• Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol 2011;38:10-20
   PubMed Web of Science ®Google Scholar
• Murakami M, Nishimoto N. The value of blocking IL-6 outside of rheumatoid arthritis: current perspective. Curr Opin Rheumatol 2011;23:273-7
   PubMed Web of Science ®Google Scholar
• Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 2011;121:3375-83
   PubMed Web of Science ®Google Scholar
• Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 2011;1813:878-88
   PubMed Web of Science ®Google Scholar
• Rose-John S, Mitsuyama K, Matsumoto S, Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease. Curr Pharm Des 2009;15:2095-103
   PubMedGoogle Scholar
• Waage A, Brandtzaeg P, Halstensen A, The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med 1989;169:333-8
   PubMed Web of Science ®Google Scholar
• Chalaris A, Rabe B, Paliga K, Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. Blood 2007;110:1748-55
   PubMed Web of Science ®Google Scholar
• Scheller J, Chalaris A, Garbers C, Rose-John S. ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends Immunol 2011;32:380-7
   PubMed Web of Science ®Google Scholar
• Garbers C, Janner N, Chalaris A, Species specificity of ADAM10 and ADAM17 proteins in interleukin-6 (IL-6) trans-signaling and novel role of ADAM10 in inducible IL-6 receptor shedding. J Biol Chem 2011;286:14804-11
   PubMed Web of Science ®Google Scholar
• Alexopoulou L, Kranidioti K, Xanthoulea S, Transmembrane TNF protects mutant mice against intracellular bacterial infections, chronic inflammation and autoimmunity. Eur J Immunol 2006;36:2768-80
   PubMed Web of Science ®Google Scholar
• Peters M, Jacobs S, Ehlers M, The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J Exp Med 1996;183:1399-406
   PubMed Web of Science ®Google Scholar
• Peters M, Blinn G, Solem F, In vivo and in vitro activities of the gp130-stimulating designer cytokine Hyper-IL-6. J Immunol 1998;161:3575-81
   PubMed Web of Science ®Google Scholar
• Atreya R, Mudter J, Finotto S, Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med 2000;6:583-8
   PubMed Web of Science ®Google Scholar
• Lo CW, Chen MW, Hsiao M, IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. Cancer Res 2011;71:424-34
   PubMed Web of Science ®Google Scholar
• Honda M, Yamamoto S, Cheng M, Human soluble IL-6 receptor: its detection and enhanced release by HIV infection. J Immunol 1992;148:2175-80
   PubMed Web of Science ®Google Scholar
• Lorenzen I, Shang W, Perbandt M, The structure of the unliganded extracellular domain of the interleukin-6 signal transducer gp130 in solution. Eur J Cell Biol 2011;90:515-20
   PubMedGoogle Scholar
• Jostock T, Mullberg J, Ozbek S, Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem 2001;268:160-7
   PubMedGoogle Scholar
• Garbers C, Thaiss W, Jones GW, Inhibition of classic signaling is a novel function of soluble gp130 which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J Biol Chem 2011;286:42959-70
   PubMed Web of Science ®Google Scholar
• Scheller J, Schuster B, Holscher C, No inhibition of IL-27 signaling by soluble gp130. Biochem Biophys Res Commun 2005;326:724-8
   PubMed Web of Science ®Google Scholar
• Schuett H, Oestreich R, Waetzig GH, Transsignaling of Interleukin-6 Crucially Contributes to Atherosclerosis in Mice. Arterioscler Thromb Vasc Biol 2012;32:281-90
   PubMed Web of Science ®Google Scholar
• Tenhumberg S, Waetzig GH, Chalaris A, Structure-guided optimization of the interleukin-6 trans-signaling antagonist sgp130. J Biol Chem 2008;283:27200-7
   PubMed Web of Science ®Google Scholar
• Appenheimer MM, Girard RA, Chen Q, Conservation of IL-6 trans-signaling mechanisms controlling L-selectin adhesion by fever-range thermal stress. Eur J Immunol 2007;37:2856-67
   PubMed Web of Science ®Google Scholar
• Igawa T, Ishii S, Tachibana T, Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol 2010;28:1203-7
   PubMed Web of Science ®Google Scholar
• Lissilaa R, Buatois V, Magistrelli G, Although IL-6 trans-signaling is sufficient to drive local immune responses, classical IL-6 signaling is obligate for the induction of T cell-mediated autoimmunity. J Immunol 2010;185:5512-21
   PubMed Web of Science ®Google Scholar
• Rose-John S, Waetzig GH, Scheller J, The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin Ther Targets 2007;11:613-24
   PubMed Web of Science ®Google Scholar
• Rabe B, Chalaris A, May U, Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood 2008;111:1021-8
   PubMed Web of Science ®Google Scholar
• Lesina M, Kurkowski MU, Ludes K, Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 2011;19:456-69
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Kanakura Y, Aozasa K, Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005;106:2627-32
   PubMed Web of Science ®Google Scholar
• Wallenius V, Wallenius K, Ahren B, Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 2002;8:75-9
   PubMed Web of Science ®Google Scholar
• Matthews VB, Allen TL, Risis S, Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance. Diabetologia 2010;53:2431-41
   PubMed Web of Science ®Google Scholar
• Ellingsgaard H, Hauselmann I, Schuler B, Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med 2011;17:1481-9
   PubMed Web of Science ®Google Scholar
• Ellingsgaard H, Ehses JA, Hammar EB, Interleukin-6 regulates pancreatic alpha-cell mass expansion. Proc Natl Acad Sci USA 2008;105:13163-8
   PubMed Web of Science ®Google Scholar
• Drucker C, Rabe B, Chalaris A, Interleukin-6 trans-signaling regulates glycogen consumption after D-galactosamine-induced liver damage. J Interferon Cytokine Res 2009;29:711-18
   PubMedGoogle Scholar
• Gewiese-Rabsch J, Drucker C, Malchow S, Role of IL-6 trans-signaling in CClinduced liver damage. Biochim Biophys Acta 2010;1802:1054-61
   PubMedGoogle Scholar
• Nechemia-Arbely Y, Shriki A, Denz U, Early hepatocyte DNA synthetic response posthepatectomy is modulated by IL-6 trans-signaling and PI3K/AKT activation. J Hepatol 2011;54:922-9
   PubMedGoogle Scholar
• Malchow S, Thaiss W, Janner N, Essential role of neutrophil mobilization in concanavalin A-induced hepatitis is based on classic IL-6 signaling but not on IL-6 trans-signaling. Biochim Biophys Acta 2011;1812:290-301
   PubMedGoogle Scholar
• Chen Q, Wang WC, Bruce R, Central role of IL-6 receptor signal-transducing chain gp130 in activation of L-selectin adhesion by fever-range thermal stress. Immunity 2004;20:59-70
   PubMed Web of Science ®Google Scholar
• Chen Q, Fisher DT, Clancy KA, Fever-range thermal stress promotes lymphocyte trafficking across high endothelial venules via an interleukin 6 trans-signaling mechanism. Nat Immunol 2006;7:1299-308
   PubMed Web of Science ®Google Scholar
• Fisher DT, Chen Q, Skitzki JJ, IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. J Clin Invest 2011;121:3846-59
   PubMed Web of Science ®Google Scholar
• Linker RA, Luhder F, Kallen KJ, IL-6 transsignalling modulates the early effector phase of EAE and targets the blood-brain barrier. J Neuroimmunol 2008;205:64-72
   PubMedGoogle Scholar
• Doganci A, Eigenbrod T, Krug N, The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo. J Clin Invest 2005;115:313-25
   PubMed Web of Science ®Google Scholar
• Finotto S, Eigenbrod T, Karwot R, Local blockade of IL-6R signaling induces lung CD4+ T cell apoptosis in a murine model of asthma via regulatory T cells. Int Immunol 2007;19:685-93
   PubMedGoogle Scholar
• Coles B, Fielding CA, Rose-John S, Classic interleukin-6 receptor signaling and interleukin-6 trans-signaling differentially control angiotensin II-dependent hypertension, cardiac signal transducer and activator of transcription-3 activation, and vascular hypertrophy in vivo. Am J Pathol 2007;171:315-25
   Google Scholar
• Nowell MA, Richards PJ, Horiuchi S, Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J Immunol 2003;171:3202-9
   PubMed Web of Science ®Google Scholar
• Richards PJ, Nowell MA, Horiuchi S, Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis. Arthritis Rheum 2006;54:1662-72
   PubMedGoogle Scholar
• Nowell MA, Williams AS, Carty SA, Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis. J Immunol 2009;182:613-22
   PubMed Web of Science ®Google Scholar
• Mitsuyama K, Matsumoto S, Rose-John S, STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/Yit mice. Gut 2006;55:1263-9
   PubMedGoogle Scholar
• Jones GW, McLoughlin RM, Hammond VJ, Loss of CD4+ T cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells. J Immunol 2010;184:2130-9
   PubMedGoogle Scholar
• Matsumoto S, Hara T, Mitsuyama K, Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model. J Immunol 2010;184:1543-51
   PubMed Web of Science ®Google Scholar
• Montufar-Solis D, Garza T, Vigneswaran N, Klein JR. Soluble gp130 promotes intestinal epithelial hyperplasia during reovirus infection. Int J Exp Pathol 2010;91:276-80
   PubMedGoogle Scholar
• Rodriguez N, Dietrich H, Mossbrugger I, Increased inflammation and impaired resistance to Chlamydophila pneumoniae infection in Dusp1(-/-) mice: critical role of IL-6. J Leukoc Biol 2010;88:579-87
   PubMedGoogle Scholar
• Kleemann R, Zadelaar S, Kooistra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc Res 2008;79:360-76
   PubMed Web of Science ®Google Scholar
• Schuett H, Luchtefeld M, Grothusen C, How much is too much? Interleukin-6 and its signalling in atherosclerosis. Thromb Haemost 2009;102:215-22
   PubMed Web of Science ®Google Scholar
• Becker C, Fantini MC, Schramm C, TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004;21:491-501
   PubMed Web of Science ®Google Scholar
• Greenhill CJ, Rose-John S, Lissilaa R, IL-6 trans-signaling modulates TLR4-dependent inflammatory responses via STAT3. J Immunol 2011;186:1199-208
   PubMed Web of Science ®Google Scholar
• Grivennikov S, Karin E, Terzic J, IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009;15:103-13
   PubMed Web of Science ®Google Scholar
• Bollrath J, Phesse TJ, von Burstin VA, gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009;15:91-102
   PubMed Web of Science ®Google Scholar
• Panja A, Siden E, Mayer L. Synthesis and regulation of accessory/proinflammatory cytokines by intestinal epithelial cells. Clin Exp Immunol 1995;100:298-305
   PubMedGoogle Scholar
• Becker C, Fantini MC, Wirtz S, IL-6 signaling promotes tumor growth in colorectal cancer. Cell Cycle 2005;4:217-20
   PubMed Web of Science ®Google Scholar
• Barkhausen T, Tschernig T, Rosenstiel P, Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model. Crit Care Med 2011;39:1407-13
   PubMed Web of Science ®Google Scholar
• Dann SM, Spehlmann ME, Hammond DC, IL-6-dependent mucosal protection prevents establishment of a microbial niche for attaching/effacing lesion-forming enteric bacterial pathogens. J Immunol 2008;180:6816-26
   PubMed Web of Science ®Google Scholar
• Kopf M, Baumann H, Freer G, Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994;368:339-42
   PubMed Web of Science ®Google Scholar
• Ladel CH, Blum C, Dreher A, Lethal tuberculosis in interleukin-6-deficient mutant mice. Infect Immun 1997;65:4843-9
   PubMed Web of Science ®Google Scholar
• Dube PH, Handley SA, Lewis J, Miller VL. Protective role of interleukin-6 during Yersinia enterocolitica infection is mediated through the modulation of inflammatory cytokines. Infect Immun 2004;72:3561-70
   PubMed Web of Science ®Google Scholar